US 11,970,498 B2
CDK2 inhibitors
Douglas Wilson, Ayer, MA (US); Neil Bifulco, Jr., Sudbury, MA (US); Natasja Brooijmans, Boston, MA (US); Joseph L. Kim, Wayland, MA (US); Philip D. Ramsden, Cambridge, MA (US); Richard Vargas, Cambridge, MA (US); and Steven Mark Wenglowsky, Cambridge, MA (US)
Assigned to BLUEPRINT MEDICINES CORPORATION, Cambridge, MA (US)
Filed by BLUEPRINT MEDICINES CORPORATION, Cambridge, MA (US)
Filed on Feb. 8, 2023, as Appl. No. 18/166,178.
Application 18/166,178 is a continuation of application No. 17/850,453, filed on Jun. 27, 2022.
Claims priority of provisional application 63/215,901, filed on Jun. 28, 2021.
Prior Publication US 2023/0322791 A1, Oct. 12, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 487/04 (2006.01); A61K 31/4985 (2006.01); A61K 31/519 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07D 519/00 (2006.01)
CPC C07D 487/04 (2013.01) [C07D 519/00 (2013.01); C07B 2200/05 (2013.01)] 26 Claims
 
1. A pharmaceutically acceptable salt of a compound selected from the group consisting of:

OG Complex Work Unit Chemistry